At the 65th ASH Annual Meeting, Peihua Lu, MD, highlights the promising efficacy and safety outcomes of NS7CAR T-cell therapy as a potential bridging therapy for patients with CD7-positive acute myeloid leukemia.
At the 65th ASH Annual Meeting, Peihua Lu, MD, highlights the promising efficacy and safety outcomes of NS7CAR T-cell therapy as a potential bridging therapy for patients with CD7-positive acute myeloid leukemia.
At the 65th ASH Annual Meeting,...